Protocol I4V-MC-JAHN: A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients with Atopic Dermatitis
Phase of Trial: Phase III
Latest Information Update: 26 Jun 2018
At a glance
- Drugs Baricitinib (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms BREEZE-AD3
- Sponsors Eli Lilly
- 09 Apr 2018 Planned End Date changed from 9 Mar 2021 to 19 Jan 2021.
- 09 Apr 2018 Planned primary completion date changed from 7 Feb 2020 to 21 Dec 2020.
- 09 Apr 2018 Status changed from not yet recruiting to recruiting.